ClinicalTrials.gg
RecruitingNCT07158476Updated Oct 24, 2025

Efficacy of Methylprednisolone for Pain Control After ACL Repair

A Phase 4 interventional study of Meloxicam 15 mg and Medrol 4 MG Oral Tablet Includes Medrol Dosepak in ACL Surgery and Pain Management, sponsored by St. Louis University. Recruiting at 1 site in United States. Open to participants aged 13 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by St. Louis University · Phase 4, Interventional, and Supportive care

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
13 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing meloxicam in Pain — 1 open to participants now, 1 under way, none of them phase 3. Meloxicam · Pain.

Planned enrollment
8th of 10
90 · median 210
Started
2025
the only one that year
Phase 4
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
1 of 10
St. Louis University

Among the 10 studies testing meloxicam in Pain, this one is the 8th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 4, and was the 10th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 10 studies testing meloxicam in Pain is open now, in 1 country.

By country, each count listing its studies:

About meloxicam

Meloxicam: first FDA approval 2000 (MOBIC), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 13 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing meloxicam in Pain, or all of them as a file.
02

Study summary

Opioids are commonly used after orthopedic surgery for pain control but have been shown to increase complications, surgeries, readmissions, and risk for opioid use disorder. The purpose of this study is to investigate the impact of adding a methylprednisolone taper to the pain regimen after ACL repair surgery to determine if this results in decreased postoperative pain and opioid use without increasing complications.

Read the detailed description

The study is to include consecutive patients who undergo ACL repair by fellowship trained surgeons at a single institution with minimum 12 week follow up. All patients between the ages of 13-50 who are willing and able to provide informed consent will be included. Patients will be assessed preoperatively and then at 2 weeks, 6 weeks,12 weeks, and 1 year clinic visits, which is standard of care. The patient will fill out 2 questions on the MyCap app the day of surgery and for 14 days following surgery for pain scores and 15 days for amount of opioid pills consumed the day prior. Patient demographic, comorbidity, and surgical data will be collected from the medical record, including age, sex, BMI, smoking status, and diabetic status.

Patients will be randomized to the treatment or control group. The treatment group will receive the following pain regimen after surgery: Medrol dose pack, Meloxicam, Hydrocodone/Acetaminophen, and Gabapentin. The control group will be prescribed: Ketoralac, Hydrocodone/Acetaminophen, and Gabapentin. Pain reporting and opioid consumption will be assessed via the MyCap app for two weeks following surgery.

Patients will be followed at standard of care clinic appointments for 1 year. PROMs data will be collected at that time, in addition to any complications.

03

Conditions studied

  • ACL Surgery
  • Pain Management

Browse trials for

Keywords

  • pain
  • opioids
  • orthopedic surgery
04

Who can participate

Ages eligible
13 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient undergoing ACL repair or ACL reconstruction with tendon autograft
  • Age 13-50 years old
  • Able to provide or parent/legal guardian is able for minors

Exclusion criteria

Exclusion Criteria:

  • Concurrent and significant injury to other bones or organs (Injury Severity Score of 4 or greater)
  • Revision ACL reconstruction
  • Concomitant additional ligament reconstruction or high tibial osteotomy
  • A history of alcohol abuse, substance abuse or chronic opioid use (filled opioid medication ×2 within 6 months of the surgery)
  • A history of renal failure (\<60 mL/min/1.73 m2), liver dysfunction (child class, >B), severe heart disease ( Class 4), diabetes, neurological or psychiatric diseases that may affect pain perception, and pre-existing immune suppression.
  • A history or active peptic ulcer disease, gastrointestinal bleeding, or current use of anticoagulation.
  • Patients currently taking oral or injectable and those who have taken either within 1 month of the procedure.
  • Patients who are currently pregnant.
  • Patients who are unable to undergo the multimodal pain standardized protocol including those with comorbidities or medical allergies precluding the use of corticosteroids, gabapentin, hydrocodone, acetaminophen, ketorolac, and/or meloxicam.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Medrol group

    Patients will receive Medrol dose pack, Meloxicam, Hydrocodone/Acetaminophen, and Gabapentin as pain regimen upon discharge from surgery.

    Drug: Meloxicam 15 mg · Drug: Medrol 4 MG Oral Tablet Includes Medrol Dosepak · Drug: Gabapentin 300 mg · Drug: Hydrocodone 5Mg/Acetaminophen 325Mg Tab

  • Active comparator
    No Medrol group

    Patients will receive Ketorolac, Hydrocodone/Acetaminophen, and Gabapentin as pain regimen upon discharge from surgery.

    Drug: Gabapentin 300 mg · Drug: Hydrocodone 5Mg/Acetaminophen 325Mg Tab · Drug: Ketorolac 10 Mg Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale (NRS) pain scores

    Zero is equivalent to no pain and 10 indicates the worst possible pain

    Time frame: Post-op days 0-14, 2 weeks, 6 weeks, and 12 weeks

Secondary outcomes

  1. Opioid consumption after surgery

    Calculated using Morphine milligram equivalents (MME)

    Time frame: 0-14 days postoperative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2030, 59 months after the start.

Of 280 non-industry phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 59 months is above that.

Counting every sponsor, half of 295 studies reached it within 18 months; a quarter within 8 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 5, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Sep 2030
CompletionEst.
Sep 2031
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07158476
Responsible party
Scott Kaar, MD (Professor, Orthopaedic Surgery, St. Louis University) — Principal investigator
First posted
Sep 5, 2025
Start date
Oct 21, 2025
Primary completion
Sep 2030 (estimated)
Completion
Sep 2031 (estimated)
Last update
Oct 24, 2025

Study contacts

Scott Kaar
Contact
scott.kaar@ssmhealth.com
314-617-3405
Allison Gruender
Contact
allison.gruender@health.slu.edu
314-617-3406
Scott Kaar, MD
principal investigator · St. Louis University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meloxicam · Methylprednisolone · Ketorolac

Start the discussion